Clinical trials: Atopic Dermatitis, completed
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.
- Trial name
- ADvantage (NCT05149313)
- Testing
- Lebrikizumab
- Where
- 48 sites in Austria, Belgium and 6 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis (AD)
A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis
This is a multicenter, randomized, double-blind, vehicle-controlled phase III study of MH004 Ointment with a 44-week open-label long-term safety extension period.
- Trial name
- NCT07185282
- Testing
- MH004 Ointment, Vehicle Ointment
- Where
- China
- Volunteers
- 375 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Atopic Dermatitis
Effects of Lactobacillus Reuteri Plus Vitamin D3 in Children With Atopic Dermatitis
The purpose of this study is to evaluate in a randomized, double-blinded, controlled trial, whether a new food supplement containing Lactobacillus reuteri DSM 17938 and vitamin D3 (Reuterin® D3) may improve the SCORAD in…
- Trial name
- NCT02945683
- Testing
- Reuterin D3
- Where
- Italy
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Noos S.r.l.
Moderate-to-severe Atopic Dermatitis
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Primary Objective: Part A To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score To determine the entry criterion…
- Trial name
- NEURADAD (NCT05203380)
- Testing
- dupilumab
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic
Study Of Atopic Dermatitis In Pediatrics
To verify of cetirizine dry syrup to ketotifen dry syrup in the change in the severity of pruritus of the treatment period.
- Trial name
- NCT00257569
- Testing
- Cetirizine Dry Syrup
- Volunteers
- 278 people
- Sponsor
- GlaxoSmithKline
Dermatitis, Atopic
Intervention Study to Evaluate a Probiotic in Mild Atopic Dermatitis Young Patients
The aim of the study is to evaluate the beneficial effect of a probiotic preparation with an antiinflammatory and modulating activity on immunological processes, with positive results on different inflammatory and atopic…
- Trial name
- NCT02585986
- Testing
- Probiotic
- Where
- Spain
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Atopic Dermatitis
Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants
The goal of this study is to determine what effect Cetaphil® Restoraderm® system has on babies' skin versus Johnson \& Johnson baby lotion and skin cleanser.
- Trial name
- NCT01375205
- Testing
- Cetaphil Restoraderm, Standard of Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Oregon Health and Science University
Pruritus, Atopic Dermatitis
Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus
To demonstrate the ability of Aurstat to reduce pruritus in subjects with mild to moderate atopic dermatitis. Efficacy results will be based on subject assessment, IGA, and photographic evidence based on ordinal scales for…
- Trial name
- AUR0613 (NCT01905631)
- Testing
- Aurstat Anti-Itch Hydrogel (Aurstat)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Center for Clinical and Cosmetic Research
Atopic Dermatitis
Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.
- Trial name
- NCT03824405
- Testing
- BTX 1204, Vehicle
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 200 people
- Sponsor
- Botanix Pharmaceuticals
Atopic Dermatitis
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
- Trial name
- NCT03587805
- Testing
- Tralokinumab
- Where
- 309 sites in United States, Belgium and 9 more
- Volunteers
- 1,672 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Skin Tape Transcriptome Methods in Children
This pilot study will evaluate new methods for the collection, storage, shipment, and RNA extraction of skin tape specimens from children with atopic dermatitis (AD) that will facilitate the multi-center SunBeam Birth Cohort…
- Trial name
- NCT04180644
- Testing
- Skin tape strips
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Atopic Dermatitis
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of age with moderate to severe AD.
- Trial name
- JADE TEEN (NCT03796676)
- Testing
- PF-04965842, PF04965842
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 287 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
Long-term tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis and prevent…
- Trial name
- NCT00480610
- Testing
- tacrolimus ointment
- Where
- 22 sites in Austria, Belgium and 11 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Inc
Moderate to Severe Atopic Hand and Foot Dermatitis
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients with atopic hand and foot dermatitis.
- Trial name
- NCT04417894
- Testing
- dupilumab
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 133 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis
The purpose of this study is to determine if an asynchronous online model of teledermatology can achieve similar clinical outcomes as compared to conventional in-office care for the management of atopic dermatitis.
- Trial name
- NCT00985894
- Testing
- Online Teledermatology Care, Conventional in Office Care
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of California, Davis
Atopic Dermatitis
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.
- Trial name
- ROCKET-Outpost (NCT06224192)
- Testing
- Rocatinlimab Prefilled Syringe, Rocatinlimab AI
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 151 people
- Sponsor
- Amgen
Dermatologic Disease
A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone
One of the most frequent skin conditions is atopic dermatitis (AD), characterized by its pruritic inflammation effect. Where the prevalence of AD increased in the last three decades by two or three folds worldwide, especially in…
- Trial name
- NCT05607901
- Testing
- Tacrolimus ointment, Hydrocortisone 1% cream
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in…
- Trial name
- NCT03911401
- Testing
- 0.3% OPA-15406, 1% OPA-15406
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
- Trial name
- ADjoin (NCT04392154)
- Testing
- Lebrikizumab
- Where
- 321 sites in United States, Australia and 14 more
- Volunteers
- 1,153 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and…
- Trial name
- NCT01139450
- Testing
- 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
- Where
- United States
- Volunteers
- 899 people
- Sponsor
- Fougera Pharmaceuticals Inc.